

Minutes

IBC

Meeting Date:

July 13, 2026

Minutes Status:

In Progress

Meeting Location

Remote Via Zoom

Meeting Attendance

Member	Attended	Voting	Staff	Scientific	Affiliated	Committee	Expertise	Job Title
						Member Role		
Chistoserdov, Andrei Ph.D.	No	Yes	No	Yes	Yes	Biosafety Officer	Microbiology	Professor
Hayes, Chris MD	Yes	Yes	No	Yes	Yes	Member	Public Health	Retired Physician Director of Process Analytics and Process Chemistry
Holmes, William	Yes	Yes	No	Yes	Yes	Chair	Microbiology	GOHSEP Region 4 Coordinator
John, Lee III	No	Yes	No	No	No	Non-affiliated member	Public Health	Professor
Louka, Febee	No	Yes	No	Yes	Yes	Member	Environmental Safety	Occupational Health Program Coordinator
Miller, Lindsey	Yes	Yes	No	Yes	Yes	Member	Occupational Health	Chief Operating Officer
OShea, Brian	Yes	Yes	No	Yes	Yes	Member	Animals, Microbiology	Research Compliance Coordinator
Ruiz, Steph non-admin (Alt)	Yes	No	Yes	Yes	Yes	Ex-Officio	Animals, Microbiology	Director, Office of Research Integrity
Schneider-Broussard, Robin Ph.D.	No	Yes	Yes	Yes	Yes	Ex-Officio, Non-voting	Animals, rDNA	Senior Clinical Veterinarian
Smith, Josh DVM	Yes	Yes	No	Yes	Yes	Member	Animals	Marketing & Sales Manager
Toups, Carl BGS	No	Yes	No	No	No	Non-affiliated member	Animals	

Wang, YiHong	Yes	Yes	No	Yes	Yes	Member	Plants, rDNA	Associate Professor
Wininger, Carl B.S.	Yes	Yes	No	Yes	Yes	Vice Chair	Environmental Safety, Occupational Health	Director of Environmental, Health & Safety

Call to Order

Guest – S. H.

Meeting starts at 10:03 AM

Review of Minutes

- Minutes from the last two meetings were accepted.

Review of Old Business

Review of New Business

IBC-26-002 new protocol

- The committee members agreed the listed BSO inspection date needs revision, the PI should attach general biosafety protocols to the application as well as personnel training documents and/or CVs.
- Change Biosafety Level classifications from BL2 to BL2-N
- Motion to send back to PI for revision, and those revisions will be reviewed by BSO and Chair once more following changes, and if changes are sufficient, the protocol will be approved.

IBC-24-002 amended protocol

- IBC discussed the change in PI, and that training documents and CVs for all personnel listed on the application should be included.
- Change Biosafety Level classifications from BL2 to BL2-N
- Motion to send back to PI for revision, and those revisions will be reviewed by BSO and Chair once more following changes, and if changes are sufficient, the protocol will be approved.

Project Number	IBC-24-002
Project Title	Research Studies in SIV or SHIV-infected Monkeys
Principal Investigator	Goetzmann, Jason DVM
Project Summary	The work described here is intended to establish and/or confirm infectious and immunization animal models, establish optimal dose for future studies (titration) and generation of biological samples (viral stocks) of new, current, and emerging pathogens for in vitro studies/ research into pathogenesis, prevention, and therapeutics. Although an infectious agent model may have been established (per literature), animal model confirmation and establishment of optimal dose of new viral/bacterial stock is necessary to ensure sustainable and reproducible results can be obtained when evaluating potential studies to avoid unnecessary/repeat studies in NHP animal models. Studies will also be conducted to establish a relationship between pharmacokinetic and pharmacodynamic measures for antiviral drugs such as reverse transcriptase, integrase and protease inhibitors in SIV/SHIV- or dengue-infected monkeys. The results from these studies will be valuable in understanding the efficacy of currently marketed antiviral treatments and for guiding dose selection and dosing intervals for the development of future innovative, safe and effective antiviral therapies for HIV and dengue fever.
NIH Guidelines	Section III-D-1.
Risk Assessment	RG2
Biosafety Level	BL2
Project Number	IBC-26-002
Project Title	Antiviral Immunization against Ebola Bundibugyo in Cynomolgus Macaques
Principal Investigator	Goetzmann, Jason DVM
Project Summary	Proposed research includes vaccination of subjects (prime vaccination only) and subsequent sample collections to monitor immunological status by sponsor defined assays. Samples will only include blood samples Subjects will be transferred to awaiting ABSL-4 facility for challenge to support likely vaccine candidate proceeding to human clinical trials.
NIH Guidelines	Section III-D-1-a.
Risk Assessment	RG1

Biosafety Level

BL2

Other Business

Schedule Next Meeting

TBA

Adjourn

11:45 AM